Investing.com -- Abbott (NYSE: ABT) shares are trading higher premarket on Thursday after the company reported second-quarter earnings, topping consensus expectations and raising its full-year earnings guidance.

Adjusted earnings per share came in at $1.31, exceeding the analyst estimate of $1.28, as the healthcare company posted revenue of $12.59 billion, surpassing the consensus estimate of $12.52 billion. Revenue increased 13.0% on a reported basis and 4.8% on a comparable basis compared to the same quarter last year.

The company raised its full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to its previous range of $5.38 to $5.58. The midpoint of $5.53 exceeds the analyst consensus of $5.48. Abbott reaffirmed its full-year 2026 comparable sales growth guidance of 6.5% to 7.5%. The company also projects third-quarter 2026 adjusted diluted EPS of $1.38 to $1.46.

Shares are up 2.5% premarket following the announcement.

"Our second-quarter results reflect the momentum we are building," said Robert B. Ford, chairman and chief executive officer, Abbott. "We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year."

Medical Devices led the quarter with sales of $5.85 billion, up 9.0% on a reported basis and 8.4% on a comparable basis. Electrophysiology grew in the low-teens while Rhythm Management, Diabetes Care, and Heart Failure posted high-single-digit growth. In Diabetes Care, continuous glucose monitor sales grew 11.0% on a reported basis and 9.5% on a comparable basis.

Diagnostics sales increased 42.3% on a reported basis and 2.9% on a comparable basis to $3.09 billion. Cancer Diagnostics results were driven by mid-teens growth of Cologuard, benefiting from a growing base of both new and repeat users. Core Laboratory Diagnostics showed strong growth in the U.S. and Latin America, while Rapid and Molecular Diagnostics reflected lower sales of respiratory virus tests compared to the prior year.

Established Pharmaceuticals sales rose 8.4% on a reported basis and 8.7% on a comparable basis to $1.50 billion, led by double-digit growth in several countries across Latin America and Asia Pacific. Nutrition sales decreased 3.1% on a reported basis and 3.6% on a comparable basis to $2.14 billion, reflecting lower sales volumes and strategic pricing actions implemented in the fourth quarter of 2025.